Verinurad Explained

Legal Status:	Investigational
Synonyms:	RDEA-3170; RDEA3170
Cas Number:	1352792-74-5
Pubchem:	54767229
Drugbank:	DB11873
Iuphar Ligand:	9327
Unii:	12WJ62D047
Chembl:	3707347
Kegg:	D11129
Iupac Name:	2-[3-(4-Cyanonaphthalen-1-yl)pyridin-4-yl]sulfanyl-2-methylpropanoic acid
Stdinchi:	1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)
Stdinchikey:	YYBOLPLTQDKXPM-UHFFFAOYSA-N
Smiles:	CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N
C:	20
H:	16
N:	2
O:	2
S:	1

Verinurad is a selective URAT1 inhibitor developed for gout and heart failure by AstraZeneca.^{[1] [2] [3]}

Notes and References

1. Johansson . Susanne . Han . David . Hunt . Thomas . Björck . Karin . Florica . Delia . Gillen . Michael . Hall . Jesse . Erlandsson . Fredrik . Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants . Pharmacology Research & Perspectives . June 2022 . 10 . 3 . e00929 . 10.1002/prp2.929. 35593744 . 9121888 .
2. Fitz-Patrick . David . Roberson . Kent . Niwa . Kiyoshi . Fujimura . Takabumi . Mori . Koji . Hall . Jesse . Yan . Xiaohong . Shen . Zancong . Liu . Sha . Ito . Yasushi . Baumgartner . Scott . Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials . Modern Rheumatology . 2 November 2019 . 29 . 6 . 1042–1052 . 10.1080/14397595.2018.1538003. 30334639 . 52988677 . free .
3. Tan . Philip K. . Liu . Sha . Gunic . Esmir . Miner . Jeffrey N. . Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout . Scientific Reports . 6 April 2017 . 7 . 1 . 665 . 10.1038/s41598-017-00706-7 . 28386072 . 5429603 . 2017NatSR...7..665T . en . 2045-2322.